首页> 外文期刊>British Journal of Clinical Pharmacology >Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol).
【24h】

Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol).

机译:对法国药物警戒系统使用三步2镇痛药的报告药物不良反应率:右丙氧芬,曲马多和可待因(与扑热息痛合用)。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Three 'weak' opioid analgesics in association with paracetamol are marketed in France as step 2 analgesics: dextropropoxyphene, tramadol and codeine. These combinations are involved in several adverse drug reactions (ADRs), but no data are available about their comparative reporting rate. The aim was to compare the reporting rate of ADRs between tramadol/paracetamol (TRM+P), codeine/paracetamol (COD+P) and dextropropoxyphene/paracetamol (DXP+P). METHODS: All spontaneous reports submitted to the French Pharmacovigilance Database from 1 January 1987 to 31 December 2006 suspected to be induced by one of the three step 2 analgesic combinations (DXP+P, TRM+P, COD+P) were extracted. Their consumption for the same period was obtained from the French Drug Agency. The number of ADRs, serious ADRs and different organ classes of ADRs were compared according to their consumption. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each variable using DXP+P as reference. RESULTS: The reporting rate of ADRs was calculated as 24.9/100 000 person-years for DXP+P, 44.5/100 000 person-years for TRM+P and 12.5/100 000 person-years for COD+P. The reporting rate (OR 0.56, 95% CI 0.50, 0.63) and 'seriousness' (OR 0.65, 95% CI 0.53, 0.80) of ADRs were significantly higher with TRM+P than with DXP+P. However, hepatobiliary ADRs were significantly more frequent with the DXP+P combination (OR 2.62, 95% CI 1.59, 4.37). In contrast, the reporting rate (OR 1.99, 95% CI 1.82, 2.18) and 'seriousness' (OR 2.64, 95% CI 2.24, 3.11) of ADRs were significantly higher with DXP+P than with COD+P. CONCLUSIONS: Among the three step 2 analgesic combinations, reporting rate and 'seriousness' of ADRs are the highest with TRM+P and the lowest with COD+P. Our study suggests that the safety profile of DXP+P is worst than that of COD+P.
机译:目的:在法国销售与扑热息痛相关的三种“弱”阿片类镇痛药,作为第2步镇痛药:右丙氧芬,曲马多和可待因。这些组合涉及几种药物不良反应(ADR),但尚无有关其比较报告率的数据。目的是比较曲马多/扑热息痛(TRM + P),可待因/扑热息痛(COD + P)和右丙氧芬/扑热息痛(DXP + P)之间的ADR报告率。方法:提取从1987年1月1日至2006年12月31日提交至法国药物警戒数据库的所有自发报告,这些报告怀疑是由三步2镇痛药组合之一(DXP + P,TRM + P,COD + P)诱导的。他们同期的消费量是从法国毒品管理局获得的。根据其消耗量比较了ADR的数量,严重的ADR和不同器官类别的ADR。使用DXP + P作为参考,计算每个变量的调整后的优势比(OR)和95%置信区间(CIs)。结果:DXP + P的ADR报告率经计算为24.9 / 10万人年,TRM + P的ADR报告率为44.5 / 10万人年,COD + P的12.5 / 10万人年。 TRM + P的ADR的报告率(OR 0.56,95%CI 0.50,0.63)和“严重性”(OR 0.65,95%CI 0.53,0.80)显着高于DXP + P。但是,DXP + P联合使用对肝胆ADR的发生率明显更高(OR 2.62,95%CI 1.59,4.37)。相比之下,DXP + P的ADR报告率(OR 1.99,95%CI 1.82,2.18)和“严重性”(OR 2.64,95%CI 2.24,3.11)显着高于COD + P。结论:在三种第二步镇痛组合中,ADR的报告率和“严重性”以TRM + P最高,而以COD + P最低。我们的研究表明,DXP + P的安全性比COD + P的安全性差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号